Ensign Peak Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.1M | Sell |
13,849
-850
| -6% | -$129K | ﹤0.01% | 883 |
|
|
2025
Q1 | $2.21M | Sell |
14,699
-1,423
| -9% | -$214K | ﹤0.01% | 863 |
|
|
2024
Q4 | $2.98M | Hold |
16,122
| – | – | 0.01% | 798 |
|
|
2024
Q3 | $3.18M | Buy |
16,122
+400
| +3% | +$78.8K | 0.01% | 772 |
|
|
2024
Q2 | $3.25M | Hold |
15,722
| – | – | 0.01% | 753 |
|
|
2024
Q1 | $4.26M | Sell |
15,722
-141
| -0.9% | -$38.2K | 0.01% | 672 |
|
|
2023
Q4 | $3.75M | Sell |
15,863
-4,249
| -21% | -$1M | 0.01% | 700 |
|
|
2023
Q3 | $3.94M | Sell |
20,112
-188
| -0.9% | -$36.8K | 0.01% | 635 |
|
|
2023
Q2 | $4.27M | Buy |
20,300
+500
| +3% | +$105K | 0.01% | 631 |
|
|
2023
Q1 | $4M | Sell |
19,800
-4,604
| -19% | -$929K | 0.01% | 633 |
|
|
2022
Q4 | $5.32M | Buy |
24,404
+9,091
| +59% | +$1.98M | 0.01% | 546 |
|
|
2022
Q3 | $3.01M | Sell |
15,313
-3,154
| -17% | -$621K | 0.01% | 651 |
|
|
2022
Q2 | $3.95M | Buy |
18,467
+150
| +0.8% | +$32.1K | 0.01% | 599 |
|
|
2022
Q1 | $5.2M | Sell |
18,317
-2,175
| -11% | -$618K | 0.01% | 580 |
|
|
2021
Q4 | $7.72M | Buy |
20,492
+13,615
| +198% | +$5.13M | 0.01% | 532 |
|
|
2021
Q3 | $2.84M | Buy |
6,877
+3,487
| +103% | +$1.44M | 0.01% | 913 |
|
|
2021
Q2 | $1.25M | Sell |
3,390
-45,519
| -93% | -$16.8M | ﹤0.01% | 1353 |
|
|
2021
Q1 | $14.2M | Sell |
48,909
-213
| -0.4% | -$61.7K | 0.03% | 359 |
|
|
2020
Q4 | $12.3M | Sell |
49,122
-1,072
| -2% | -$268K | 0.03% | 387 |
|
|
2020
Q3 | $11.4M | Buy |
50,194
+5,240
| +12% | +$1.19M | 0.03% | 420 |
|
|
2020
Q2 | $7.84M | Buy |
44,954
+4,830
| +12% | +$842K | 0.02% | 481 |
|
|
2020
Q1 | $5.06M | Sell |
40,124
-2,430
| -6% | -$307K | 0.02% | 509 |
|
|
2019
Q4 | $6.5M | Buy |
+42,554
| New | +$6.5M | 0.02% | 564 |
|